Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management

The unprecedented success of in myelofibrosis (MF) has paved the way for the development of other Janus kinase (JAK) inhibitors and other agents representing diverse drug classes and mechanisms of action in myeloproliferative neoplasms (MPNs). Other JAK inhibitors with the potential for significantly less myelosuppression or even improvement of anemia continue to be tested. This article reviews the current landscape of clinical drug development ruxolitinib in MPNs, focusing on the most promising agents and combinations.

 J Natl Compr Canc Netw

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.